Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Northwest hopes to secure more funding in first quarter

This article was originally published in Scrip

Executive Summary

Northwest Biotherapeutics hopes to secure more funding by the end of this quarter after it received $500,000 loan last month. The funding, from Toucan Partners, should finance its operations until the end of this month. The cancer-focused company has been facing financial difficulties since the latter half of last year and needs more cash to fund future clinical trials and other operating activities.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts